Ritholtz Wealth Management’s Spero Therapeutics SPRO Stock Holding History

Ritholtz Wealth Management’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$25.1K	Buy	+20,704	New	+$28.1K	﹤0.01%	1386

Other funds holding SPRO

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.25% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Capital Asset Advisory Services Williamston, Michigan $2.94B AUM 11.83% 1-Year Est. Return

Three Seasons Wealth Salt Lake City, Utah $1.12B AUM 34.1% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Ritholtz Wealth Management's SPRO Position: Q3 2026 in Review

Ritholtz Wealth Management opened a new position in Spero Therapeutics (SPRO) in Q3 2026: 20,704 shares worth $25.1K. The stake represents ﹤0.01% of the portfolio and ranks #1386 among its holdings.

17 funds tracked by Wall St. Rank hold SPRO as of Q3 2026.

Ritholtz Wealth Management held 20,704 shares of Spero Therapeutics worth $25.1K as of Q3 2026.
Spero Therapeutics was a new Ritholtz Wealth Management position in Q3 2026.
Spero Therapeutics made up ﹤0.01% of Ritholtz Wealth Management's portfolio in Q3 2026, its #1386 holding.
17 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2026.

Based on Ritholtz Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.